| Filed On | Filing |
|---|---|
| 03 Aug 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
As previously disclosed, on February 24, 2026, the Board appointed Mr. Jackson to serve as the Company’s CEO, effective August 1, 2026. On July 28, 2026, the Board took action to expand Mr. Jackson’s responsibilities and, commensurate wi... |
| 01 May 2026 |
8-K/A: Financial Statements and Exhibits
To the shareholder and the Board of Directors of Avadel Pharmaceuticals plc |
| 20 Sep 2016 |
8-K/A: Departure/Election of Directors or Officers; Compensation
(d) On September 14, 2016, in connection with the election of Nancy L. Snyderman, M.D. as a Class I director of the Company on May 26, 2016 and consistent with the “Director Compensation” section of the Company’s definitive proxy stateme... |
| 16 Apr 2015 |
8-K/A: Completion of Acquisition or Disposition of Assets
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. |
| 29 Sep 2011 |
8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more
We were previously principal accountants for Alkermes plc (formerly Antler Science Two plc) and, under the date of July 12, 2011, we reported on the balance sheet and related notes of Alkermes plc (formerly Antler Science Two plc)as of J... |
Loading...